Recently, a retrospective study investigated the efficacy and safety of regorafenib, a multitargeted kinase inhibitor, in 27 advanced melanoma patients who had previously progressed on anti-PD-1, anti-CTLA-4, and BRAFi/MEKi (12). This evidence concerns the gene PDCD1 and melanoma.